Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
Bone Marrow Transplant
.
2022 Jan;57(1):143.
doi: 10.1038/s41409-021-01523-3.
Authors
Kristina Hölig
1
,
Helmuth Schmidt
2
,
Gero Hütter
3
,
Michael Kramer
1
,
Raphael Teipel
1
,
Katharina Heidrich
1
,
Kristin Zimmer
1
,
Falk Heidenreich
1
4
,
Matthias Blechschmidt
1
,
Tigran Torosian
5
,
Rainer Ordemann
6
,
Frank Kroschinsky
1
,
Elke Rücker-Braun
1
,
Laszlo Gopsca
7
,
Eva Maria Wagner-Drouet
8
,
Uta Oelschlaegel
1
,
Alexander H Schmidt
9
,
Martin Bornhäuser
1
10
,
Gerhard Ehninger
1
,
Johannes Schetelig
11
12
Affiliations
1
Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU, Dresden, Germany.
2
Cellex Collection Center GmbH, Cologne, Germany.
3
Cellex Collection Center GmbH, Dresden, Germany.
4
DKMS gemeinnützige GmbH, Clinical Trials Unit, Dresden, Germany.
5
Fundacja DKMS Polska, Warszawa, Poland.
6
MLL Münchner Leukämielabor GmbH, München, Germany.
7
National Institute of Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, Budapest, Hungary.
8
Medizinische Klinik und Poliklinik III, Hämatologie, Internistische Onkologie, Pneumologie, Universitätsmedizin Mainz, Mainz, Germany.
9
DKMS gemeinnützige GmbH, Tübingen, Germany.
10
Center for Regenerative Therapies, Dresden, Germany.
11
Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU, Dresden, Germany. Johannes.Schetelig@uniklinikum-dresden.de.
12
DKMS gemeinnützige GmbH, Clinical Trials Unit, Dresden, Germany. Johannes.Schetelig@uniklinikum-dresden.de.
PMID:
34773089
PMCID:
PMC8732266
DOI:
10.1038/s41409-021-01523-3
No abstract available
Publication types
Published Erratum